13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma

J. M. Chow, A. L. Cheng, I. J. Su, C. H. Wang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.

Original languageEnglish
Pages (from-to)2490-2494
Number of pages5
JournalCancer
Volume67
Issue number10
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Anaplastic Large-Cell Lymphoma
Isotretinoin
Skin
Xerostomia
Hyperlipidemias
Phenotype
Biopsy
Bone and Bones
Pain
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma. / Chow, J. M.; Cheng, A. L.; Su, I. J.; Wang, C. H.

In: Cancer, Vol. 67, No. 10, 1991, p. 2490-2494.

Research output: Contribution to journalArticle

Chow, J. M. ; Cheng, A. L. ; Su, I. J. ; Wang, C. H. / 13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma. In: Cancer. 1991 ; Vol. 67, No. 10. pp. 2490-2494.
@article{935d212b8e39474ba5651a70f0dbbe60,
title = "13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma",
abstract = "A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.",
author = "Chow, {J. M.} and Cheng, {A. L.} and Su, {I. J.} and Wang, {C. H.}",
year = "1991",
language = "English",
volume = "67",
pages = "2490--2494",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - 13-cis-Retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma

AU - Chow, J. M.

AU - Cheng, A. L.

AU - Su, I. J.

AU - Wang, C. H.

PY - 1991

Y1 - 1991

N2 - A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.

AB - A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0025741719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025741719&partnerID=8YFLogxK

M3 - Article

C2 - 1849787

AN - SCOPUS:0025741719

VL - 67

SP - 2490

EP - 2494

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -